Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders

Autoimmunity Reviews

Volumn 17, Issue 2, 2018, Pages 115-124

  Tudesq, Jean Jacques ^a   Cartron, Guillaume ^a,b   Rivière, Sophie ^a   Morquin, David ^a   Iordache, Laura ^c   Mahr, Alfred ^c   Pourcher, Valérie ^d   Klouche, Kada ^a   Cerutti, Diane ^a   Le Quellec, Alain ^a   Guilpain, Philippe ^a,e  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE MONTPELLIER   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e INSERM   (France)

Author keywords

Autoimmune disease; Immunosuppression; Infection; Opportunistic infection; Rituximab

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BELIMUMAB; BENDAMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLUCOCORTICOID; IBRITUMOMAB TIUXETAN; METHOTREXATE; MYCOPHENOLATE MOFETIL; PENTAMIDINE; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; VINCRISTINE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ANTIMICROBIAL THERAPY; ATYPICAL MYCOBACTERIOSIS; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BLOODSTREAM INFECTION; BONE INFECTION; CANDIDEMIA; CELLULITIS; CENTRAL NERVOUS SYSTEM INFECTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CLINICAL OUTCOME; COHORT ANALYSIS; COLITIS; COMMON TERMINOLOGICAL CRITERIA OF ADVERSE EVENTS; CONNECTIVE TISSUE DISEASE; CRYOGLOBULINEMIA; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DACRYOCYSTITIS; DIFFUSE LARGE B CELL LYMPHOMA; DISEASE SEVERITY; DRUG INDICATION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; ESCHERICHIA COLI INFECTION; ESOPHAGITIS; ESOPHAGUS CANDIDIASIS; EVENT FREE SURVIVAL; FATALITY; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; FOLLICULAR LYMPHOMA; FOLLOW UP; GASTROINTESTINAL INFECTION; HEMATOLOGIC MALIGNANCY; HEPATOBILIARY SYSTEM INFECTION; HERPES ZOSTER; HOSPITALIZATION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; INFECTIOUS ARTHRITIS; INFUSION RELATED REACTION; INFUSION THERAPY; INTENSIVE CARE UNIT; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LENGTH OF STAY; LOWER RESPIRATORY TRACT INFECTION; LUNG INFECTION; LYMPHOCYTIC LYMPHOMA; LYMPHOMATOID GRANULOMATOSIS; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MEDICAL RECORD REVIEW; MICROSCOPIC POLYANGIITIS; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MORTALITY; MYCOSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PARASITOSIS; PNEUMOCOCCAL INFECTION; PNEUMOCYSTIS PNEUMONIA; PNEUMOCYSTOSIS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SIDE EFFECT ASSESSMENT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC MYCOSIS; TERTIARY CARE CENTER; THROMBOTIC THROMBOCYTOPENIC PURPURA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UROSEPSIS; VASCULITIS; VERY ELDERLY; VIRUS INFECTION; VIRUS PNEUMONIA; WALDENSTROEM MACROGLOBULINEMIA; HEMATOLOGIC DISEASE; PATHOLOGY; REGISTER; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; AUTOIMMUNE DISEASES; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; REGISTRIES; RETROSPECTIVE STUDIES; RITUXIMAB; TREATMENT OUTCOME;

EID: 85044478091     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.11.015     Document Type: Review

References (41)

1. Maloney, D.G., Grillo-López, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90 (1997), 2188–2195.
2. McLaughlin, P., Grillo-López, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol Off J Am Soc Clin Oncol 16 (1998), 2825–2833.
3. Gottenberg, J.-E., Guillevin, L., Lambotte, O., Combe, B., Allanore, Y., Cantagrel, A., et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64 (2005), 913–920, 10.1136/ard.2004.029694.
4. Abdulla, N.E., Ninan, M.J., Markowitz, A.B., Rituximab: current status as therapy for malignant and benign hematologic disorders. BioDrugs Clin Immunother Biopharm Gene Ther 26 (2012), 71–82, 10.2165/11599500-000000000-00000.
5. Pérez-Callejo, D., González-Rincón, J., Sánchez, A., Provencio, M., Sánchez-Beato, M., Action and resistance of monoclonal CD20 antibodies therapy in B-cell non-Hodgkin lymphomas. Cancer Treat Rev 41 (2015), 680–689, 10.1016/j.ctrv.2015.05.007.
6. Reff, M.E., Carner, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (1994), 435–445.
7. van de Veerdonk, F.L., Lauwerys, B., Marijnissen, R.J., Timmermans, K., Di Padova, F., Koenders, M.I., et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 63 (2011), 1507–1516, 10.1002/art.30314.
8. Kelesidis, T., Daikos, G., Boumpas, D., Tsiodras, S., Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 15 (2011), e2–16, 10.1016/j.ijid.2010.03.025.
9. Tony, H.-P., Burmester, G., Schulze-Koops, H., Grunke, M., Henes, J., Kötter, I., et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther, 13, 2011, R75, 10.1186/ar3337.
10. Mariette, X., Gottenberg, J.-E., Ravaud, P., Combe, B., Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 50 (2011), 222–229, 10.1093/rheumatology/keq368.
11. Tavazzi, E., Ferrante, P., Khalili, K., Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin Microbiol Infect 17 (2011), 1776–1780, 10.1111/j.1469-0691.2011.03653.x.
12. Martin-Garrido, I., Carmona, E.M., Specks, U., Limper, A.H., Pneumocystis pneumonia in patients treated with rituximab. Chest 144 (2013), 258–265, 10.1378/chest.12-0477.
13. Winthrop, K.L., Novosad, S.A., Baddley, J.W., Calabrese, L., Chiller, T., Polgreen, P., et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis 74 (2015), 2107–2116, 10.1136/annrheumdis-2015-207841.
14. Carson, K.R., Evens, A.M., Richey, E.A., Habermann, T.M., Focosi, D., Seymour, J.F., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113 (2009), 4834–4840, 10.1182/blood-2008-10-186999.
15. Stuck, A.E., Minder, C.E., Frey, F.J., Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11 (1989), 954–963.
16. Lionakis, M.S., Kontoyiannis, D.P., Glucocorticoids and invasive fungal infections. Lancet 362 (2003), 1828–1838, 10.1016/S0140-6736(03)14904-5.
17. Kronbichler, A., Jayne, D.R.W., Mayer, G., Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Investig 45 (2015), 346–368, 10.1111/eci.12410.
18. Besada, E., Bader, L., Nossent, H., Sustained hypogammaglobulinemia under rituximab maintenance therapy could increase the risk for serious infections: a report of two cases. Rheumatol Int 33 (2013), 1643–1644, 10.1007/s00296-011-2353-5.
19. Tesfa, D., Ajeganova, S., Hägglund, H., Sander, B., Fadeel, B., Hafström, I., et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 63 (2011), 2209–2214, 10.1002/art.30427.
20. Heusele, M., Clerson, P., Guery, B., Lambert, M., Launay, D., Lefevre, G., et al. Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab. Clin Rheumatol 33 (2014), 799–805, 10.1007/s10067-014-2509-2.
21. Kasi, P.M., Tawbi, H.A., Oddis, C.V., Kulkarni, H.S., Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective. Crit Care, 16, 2012, 231, 10.1186/cc11304.
22. Marco, H., Smith, R.M., Jones, R.B., Guerry, M.-J., Catapano, F., Burns, S., et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord, 15, 2014, 178, 10.1186/1471-2474-15-178.
23. Kimby, E., Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31 (2005), 456–473, 10.1016/j.ctrv.2005.05.007.
24. Ramos-Casals, M., García-Hernández, F.J., de Ramón, E., Callejas, J.L., Martínez-Berriotxoa, A., Pallarés, L., et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 28 (2010), 468–476.
25. Mariette, X., Rouanet, S., Sibilia, J., Combe, B., Le Loët, X., Tebib, J., et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis 73 (2014), 1508–1514, 10.1136/annrheumdis-2013-203480.
26. Ramos-Casals, M., Brito-Zerón, P., Muñoz, S., Soto, M.-J., BIOGEAS STUDY Group, A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 87 (2008), 345–364, 10.1097/MD.0b013e318190f170.
27. van Vollenhoven, R.F., Emery, P., Bingham, C.O., Keystone, E.C., Fleischmann, R.M., Furst, D.E., et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72 (2013), 1496–1502, 10.1136/annrheumdis-2012-201956.
28. Arad, U., Tzadok, S., Amir, S., Mandelboim, M., Mendelson, E., Wigler, I., et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine, 29(8), 2011, 1643, 10.1016/j.vaccine.2010.12.072.
29. Yamamoto, A., Sato, K., Miyoshi, F., Shindo, Y., Yoshida, Y., Yokota, K., et al. Analysis of cytokine production patterns of peripheral blood mononuclear cells from a rheumatoid arthritis patient successfully treated with rituximab. Mod Rheumatol Jpn Rheum Assoc 20 (2010), 183–187, 10.1007/s10165-009-0244-3.
30. Feuchtenberger, M., Müller, S., Roll, P., Waschbisch, A., Schäfer, A., Kneitz, C., et al. Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Open Rheumatol J 2 (2008), 81–88, 10.2174/1874312900802010081.
31. Stasi, R., Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin Hematol 47 (2010), 170–179, 10.1053/j.seminhematol.2010.01.010.
32. Kelly, M.N., Shellito, J.E., Current understanding of pneumocystis immunology. Future Microbiol 5 (2010), 43–65, 10.2217/fmb.09.116.
33. Wiley, J.A., Harmsen, A.G., CD40 ligand is required for resolution of Pneumocystis carinii pneumonia in mice. J Immunol Baltim Md 1950:155 (1995), 3525–3529.
34. Goldberg, S.L., Pecora, A.L., Alter, R.S., Kroll, M.S., Rowley, S.D., Waintraub, S.E., et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 99 (2002), 1486–1488.
35. Horwitz, S.M., Negrin, R.S., Blume, K.G., Breslin, S., Stuart, M.J., Stockerl-Goldstein, K.E., et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 103 (2004), 777–783, 10.1182/blood-2003-04-1257.
36. Toubi, E., Kessel, A., Slobodin, G., Boulman, N., Pavlotzky, E., Zisman, D., et al. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 66 (2007), 818–820, 10.1136/ard.2006.062505.
37. Thurlings, R.M., Vos, K., Wijbrandts, C.A., Zwinderman, A.H., Gerlag, D.M., Tak, P.P., Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 67 (2008), 917–925, 10.1136/ard.2007.080960.
38. Jiang, X., Mei, X., Feng, D., Wang, X., Prophylaxis and treatment of pneumocystis jiroveci pneumonia in lymphoma patients subjected to rituximab-contained therapy: a systemic review and meta-analysis. PLoS One, 10, 2015, e0122171, 10.1371/journal.pone.0122171.
39. Guillevin, L., Infections in vasculitis. Best Pract Res Clin Rheumatol 27 (2013), 19–31, 10.1016/j.berh.2013.01.004.
40. Besada, E., Nossent, J.C., Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?. Clin Rheumatol 32 (2013), 1677–1681, 10.1007/s10067-013-2293-4.
41. Charles, P., Bienvenu, B., Bonnotte, B., Gobert, P., Godmer, P., Hachulla, É., et al. Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Médicale Paris Fr 1983:42 (2013), 1317–1330, 10.1016/j.lpm.2013.08.003.